CP 3
Alternative Names: CP-3Latest Information Update: 10 Oct 2022
Price :
$50 *
At a glance
- Originator STALICLA
- Class Behavioural disorder therapies; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pervasive child development disorders
Highest Development Phases
- Preclinical Pervasive child development disorders
Most Recent Events
- 20 Sep 2022 CP 3 is available for licensing as of 20 Sep 2022. https://stalicla.com/pipeline
- 20 Sep 2022 Preclinical development in Pervasive child development disorders in Switzerland (unspecified route) (STALICLA pipeline, September 2022)